{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:56:14Z","timestamp":1792828574632,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s11102-021-01184-x","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T18:02:57Z","timestamp":1631556177000},"page":"167-179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Management of prolactinomas in children and adolescents; which factors define the response to treatment?"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3379-6407","authenticated-orcid":false,"given":"Ayfer","family":"Alikasifoglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5945-286X","authenticated-orcid":false,"given":"Nur Berna","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2390-5123","authenticated-orcid":false,"given":"Zeynep Alev","family":"Ozon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1385-2563","authenticated-orcid":false,"given":"Elmas Nazli","family":"Gonc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6345-9770","authenticated-orcid":false,"given":"Nurgun","family":"Kandemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"issue":"1","key":"1184_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11102-005-5079-0","volume":"8","author":"A Ciccarelli","year":"2005","unstructured":"Ciccarelli A, Daly AF, Beckers A (2005) The epidemiology of prolactinomas. Pituitary 8(1):3\u20136. DOI:https:\/\/doi.org\/10.1007\/s11102-005-5079-0","journal-title":"Pituitary"},{"issue":"3","key":"1184_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","volume":"72","author":"A Fernandez","year":"2010","unstructured":"Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72(3):377\u2013382. DOI:https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03667.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"1184_CR3","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1210\/jc.2006-1668","volume":"91","author":"AF Daly","year":"2006","unstructured":"Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91(12):4769\u20134775. DOI:https:\/\/doi.org\/10.1210\/jc.2006-1668","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1184_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1530\/eje-14-0144","volume":"171","author":"A Tj\u00f6rnstrand","year":"2014","unstructured":"Tj\u00f6rnstrand A, Gunnarsson K, Evert M, Holmberg E, Ragnarsson O, Ros\u00e9n T, Filipsson H, Nystr\u00f6m (2014) The incidence rate of pituitary adenomas in western Sweden for the period 2001\u20132011. Eur J Endocrinol 171(4):519\u2013526. DOI:https:\/\/doi.org\/10.1530\/eje-14-0144","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1184_CR5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1530\/eje-15-0189","volume":"173","author":"TT Agustsson","year":"2015","unstructured":"Agustsson TT, Baldvinsdottir T, Jonasson JG, Olafsdottir E, Steinthorsdottir V, Sigurdsson G, Thorsson AV, Carroll PV, Korbonits M, Benediktsson R (2015) The epidemiology of pituitary adenomas in Iceland, 1955\u20132012: a nationwide population-based study. Eur J Endocrinol 173(5):655\u2013664. DOI:https:\/\/doi.org\/10.1530\/eje-15-0189","journal-title":"Eur J Endocrinol"},{"key":"1184_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-021-01146-3","author":"BF Bitner","year":"2021","unstructured":"Bitner BF, Lehrich BM, Abiri A, Yasaka TM, Hsu FPK, Kuan EC (2021) Characteristics and overall survival in pediatric versus adult pituitary adenoma: a National Cancer Database analysis. Pituitary. DOI:https:\/\/doi.org\/10.1007\/s11102-021-01146-3","journal-title":"Pituitary"},{"issue":"1","key":"1184_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00431-017-3042-5","volume":"177","author":"A Hoffmann","year":"2018","unstructured":"Hoffmann A, Adelmann S, Lohle K, Claviez A, M\u00fcller HL (2018) Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis. Eur J Pediatr 177(1):125\u2013132. DOI:https:\/\/doi.org\/10.1007\/s00431-017-3042-5","journal-title":"Eur J Pediatr"},{"issue":"3","key":"1184_CR8","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s11102-020-01120-5","volume":"24","author":"LE Castellanos","year":"2021","unstructured":"Castellanos LE, Misra M, Smith TR, Laws ER, Iorgulescu JB (2021) The epidemiology and management patterns of pediatric pituitary tumors in the United States. Pituitary 24(3):412\u2013419. DOI:https:\/\/doi.org\/10.1007\/s11102-020-01120-5","journal-title":"Pituitary"},{"issue":"4","key":"1184_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1046\/j.1365-2265.2003.01748.x","volume":"58","author":"S Cannav\u00f2","year":"2003","unstructured":"Cannav\u00f2 S, Venturino M, Curt\u00f2 L, De Menis E, D\u2019Arrigo C, Tita P, Billeci D, Trimarchi F (2003) Clinical presentation and outcome of pituitary adenomas in teenagers. Clin Endocrinol (Oxf) 58(4):519\u2013527. DOI:https:\/\/doi.org\/10.1046\/j.1365-2265.2003.01748.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"1184_CR10","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s11102-008-0149-8","volume":"12","author":"SV Acharya","year":"2009","unstructured":"Acharya SV, Gopal RA, Bandgar TR, Joshi SR, Menon PS, Shah NS (2009) Clinical profile and long term follow up of children and adolescents with prolactinomas. Pituitary 12(3):186\u2013189. DOI:https:\/\/doi.org\/10.1007\/s11102-008-0149-8","journal-title":"Pituitary"},{"issue":"8","key":"1184_CR11","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1210\/jcem.83.8.5001","volume":"83","author":"A Colao","year":"1998","unstructured":"Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, Facciolli G, Lombardi G (1998) Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 83(8):2777\u20132780. DOI:https:\/\/doi.org\/10.1210\/jcem.83.8.5001","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1184_CR12","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1210\/jcem.79.4.7525627","volume":"79","author":"LA Kane","year":"1994","unstructured":"Kane LA, Leinung MC, Scheithauer BW, Bergstralh EJ, Laws ER Jr, Groover RV, Kovacs K, Horvath E, Zimmerman D (1994) Pituitary adenomas in childhood and adolescence. The Journal of Clinical Endocrinology Metabolism 79(4):1135\u20131140. DOI:https:\/\/doi.org\/10.1210\/jcem.79.4.7525627","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"1184_CR13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.wneu.2015.11.046","volume":"87","author":"M Shirvani","year":"2016","unstructured":"Shirvani M, Motiei-Langroudi R, Sadeghian H (2016) Outcome of microscopic transsphenoidal surgery in cushing disease: a case series of 96 patients. World Neurosurg 87:170\u2013175. https:\/\/doi.org\/10.1016\/j.wneu.2015.11.046","journal-title":"World Neurosurg"},{"issue":"1","key":"1184_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/neuros\/nyy204","volume":"85","author":"LR Barzaghi","year":"2019","unstructured":"Barzaghi LR, Losa M, Capitanio JF, Albano L, Weber G, Mortini P (2019) Pediatric pituitary adenomas: early and long-term surgical outcome in a series of 85 consecutive patients. Neurosurgery 85(1):65\u201374. https:\/\/doi.org\/10.1093\/neuros\/nyy204","journal-title":"Neurosurgery"},{"issue":"1","key":"1184_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000497331","volume":"109","author":"M Buchfelder","year":"2019","unstructured":"Buchfelder M, Zhao Y, Schlaffer SM (2019) Surgery for prolactinomas to date. Neuroendocrinology 109(1):77\u201381. https:\/\/doi.org\/10.1159\/000497331","journal-title":"Neuroendocrinology"},{"issue":"5816","key":"1184_CR16","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1136\/bmj.2.5816.743","volume":"2","author":"L Varga","year":"1972","unstructured":"Varga L, Lutterbeck PM, Pryor JS, Wenner R, Erb H (1972) Suppression of puerperal lactation with an ergot alkaloid: a double-blind study. Br Med J 2(5816):743\u2013744. DOI:https:\/\/doi.org\/10.1136\/bmj.2.5816.743","journal-title":"Br Med J"},{"issue":"14","key":"1184_CR17","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/nejm199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331(14):904\u2013909. DOI:https:\/\/doi.org\/10.1056\/nejm199410063311403","journal-title":"N Engl J Med"},{"issue":"2","key":"1184_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1210\/jc.2018-01071","volume":"104","author":"CE Stiles","year":"2018","unstructured":"Stiles CE, Tetteh-Wayoe ET, Bestwick JP, Steeds RP, Drake WM (2018) A meta-analysis of the prevalence of cardiac valvulopathy in patients with hyperprolactinemia treated with cabergoline. J Clin Endocrinol Metab 104(2):523\u2013538. https:\/\/doi.org\/10.1210\/jc.2018-01071","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1184_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1530\/eje-13-0231","volume":"169","author":"RS Auriemma","year":"2013","unstructured":"Auriemma RS, Pivonello R, Perone Y, Grasso LF, Ferreri L, Simeoli C, Iacuaniello D, Gasperi M, Colao A (2013) Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol 169(3):359\u2013366. DOI:https:\/\/doi.org\/10.1530\/eje-13-0231","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1184_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMoa054830","volume":"356","author":"R Zanettini","year":"2007","unstructured":"Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease. N Engl J Med 356(1):39\u201346. DOI:https:\/\/doi.org\/10.1056\/NEJMoa054830","journal-title":"N Engl J Med"},{"issue":"12","key":"1184_CR21","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40263-015-0293-4","volume":"29","author":"T Tran","year":"2015","unstructured":"Tran T, Brophy JM, Suissa S, Renoux C (2015) Risks of cardiac valve regurgitation and heart failure associated with Ergot- and non-Ergot-derived dopamine agonist use in patients with Parkinson\u2019s disease: a systematic review of observational studies. CNS Drugs 29(12):985\u2013998. https:\/\/doi.org\/10.1007\/s40263-015-0293-4","journal-title":"CNS Drugs"},{"key":"1184_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2020.12.008","author":"F Castinetti","year":"2020","unstructured":"Castinetti F, Albarel F, Amodru V, Cuny T, Dufour H, Graillon T, Morange I, Brue T (2020) The risks of medical treatment of prolactinoma. Ann Endocrinol (Paris). https:\/\/doi.org\/10.1016\/j.ando.2020.12.008","journal-title":"Ann Endocrinol (Paris)"},{"issue":"2","key":"1184_CR23","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273\u2013288. DOI:https:\/\/doi.org\/10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1184_CR24","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1136\/adc.51.3.170","volume":"51","author":"JM Tanner","year":"1976","unstructured":"Tanner JM, Whitehouse RH (1976) Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 51(3):170\u2013179. DOI:https:\/\/doi.org\/10.1136\/adc.51.3.170","journal-title":"Arch Dis Child"},{"key":"1184_CR25","unstructured":"Centers for Disease Control and Prevention. Growth Charts.\u00a0Available from: http:\/\/www.cdc.gov\/growthcharts"},{"key":"1184_CR26","unstructured":"Melmed S, Auchus RJ, Goldfine AB, Koenig R, Rosen CJ, and Williams RH (2020)\u00a0Williams textbook of endocrinology."},{"issue":"1","key":"1184_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/s0022-3476(97)90000-7","volume":"131","author":"J Tanner","year":"1997","unstructured":"Tanner J, Oshman D, Bahhage F, Healy M (1997) Tanner-Whitehouse bone age reference values for North American children. J Pediatr 131(1 Pt 1):34\u201340. DOI:https:\/\/doi.org\/10.1016\/s0022-3476(97)90000-7","journal-title":"J Pediatr"},{"issue":"5","key":"1184_CR28","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3171\/2010.11.Jns101369","volume":"114","author":"MC Oh","year":"2011","unstructured":"Oh MC, Aghi MK (2011) Dopamine agonist-resistant prolactinomas. J Neurosurg 114(5):1369\u20131379. DOI:https:\/\/doi.org\/10.3171\/2010.11.Jns101369","journal-title":"J Neurosurg"},{"issue":"1","key":"1184_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/cen.13156","volume":"86","author":"E Soto-Pedre","year":"2017","unstructured":"Soto-Pedre E, Newey PJ, Bevan JS, Greig N, Leese GP (2017) The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: the Prolactin Epidemiology, Audit and Research Study (PROLEARS). Clin Endocrinol (Oxf) 86(1):60\u201367. DOI:https:\/\/doi.org\/10.1111\/cen.13156","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1184_CR30","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3389\/fendo.2020.00527","volume":"11","author":"A Yang","year":"2020","unstructured":"Yang A, Cho SY, Park H, Kim MS, Kong DS, Shin HJ, Jin DK (2020) Clinical, hormonal, and neuroradiological characteristics and therapeutic outcomes of prolactinomas in children and adolescents at a Single Center. Front Endocrinol (Lausanne) 11:527. https:\/\/doi.org\/10.3389\/fendo.2020.00527","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"1184_CR31","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/cen.14394","volume":"94","author":"VB Arya","year":"2021","unstructured":"Arya VB, Aylwin SJB, Hulse T, Ajzensztejn M, Kalitsi J, Kalogirou N, Bodi I, Thomas N, Hampton T, Kapoor RR, Buchanan CR (2021) Prolactinoma in childhood and adolescence-Tumour size at presentation predicts management strategy: Single centre series and a systematic review and meta-analysis. Clin Endocrinol (Oxf) 94(3):413\u2013423. DOI:https:\/\/doi.org\/10.1111\/cen.14394","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"1184_CR32","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1210\/jc.2014-3670","volume":"100","author":"S Salenave","year":"2015","unstructured":"Salenave S, Ancelle D, Bahougne T, Raverot G, Kamenick\u00fd P, Bouligand J, Guiochon-Mantel A, Linglart A, Souchon PF, Nicolino M, Young J, Borson-Chazot F, Delemer B, Chanson P (2015) Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. J Clin Endocrinol Metab 100(3):1177\u20131186. DOI:https:\/\/doi.org\/10.1210\/jc.2014-3670","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1184_CR33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1507\/endocrj.EJ17-0268","volume":"65","author":"YM Kim","year":"2018","unstructured":"Kim YM, Seo GH, Kim YM, Choi JH, Yoo HW (2018) Broad clinical spectrum and diverse outcomes of prolactinoma with pediatric onset: medication-resistant and recurrent cases. Endocr J 65(3):307\u2013315. DOI:https:\/\/doi.org\/10.1507\/endocrj.EJ17-0268","journal-title":"Endocr J"},{"issue":"9","key":"1184_CR34","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1515\/jpem-2018-0475","volume":"32","author":"CM Brichta","year":"2019","unstructured":"Brichta CM, Wurm M, Krebs A, Schwab KO (2019) Werf-Grohmann, Start low, go slowly - mental abnormalities in young prolactinoma patients under cabergoline therapy. J Pediatr Endocrinol Metab 32(9):969\u2013977. DOI:https:\/\/doi.org\/10.1515\/jpem-2018-0475. and N. van der","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"2","key":"1184_CR35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4274\/jcrpe.galenos.2018.2018.0206","volume":"11","author":"E Eren","year":"2019","unstructured":"Eren E, T\u00f6rel Erg\u00fcr A, \u0130\u015fg\u00fcven \u015e P, \u00c7elebi Bitkin E, Berbero\u011flu M, \u015e\u0131klar Z, Ba\u015f F, Yel S, Ba\u015f S, S\u00f6b\u00fc E, Bereket A, Turan S, Sa\u011flam H, Atay Z, Ercan O, G\u00fcran T, Atabek ME, Korkmaz HA, K\u0131l\u0131n\u00e7 U\u011furlu A, Ak\u0131nc\u0131 A, D\u00f6\u011fer E, \u015eim\u015fek E, Akba\u015f ED, Abac\u0131 A, G\u00fcl \u00dc, Acar S, Mengen U\u00e7akt\u00fcrk E, Y\u0131ld\u0131z M, \u00dcnal E, Tar\u0131m \u00d6 (2019) Clinical and Laboratory Characteristics of Hyperprolactinemia in Children and Adolescents: National Survey. J Clin Res Pediatr Endocrinol 11(2):149\u2013156. DOI:https:\/\/doi.org\/10.4274\/jcrpe.galenos.2018.2018.0206","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"4","key":"1184_CR36","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.eprac.2020.09.001","volume":"27","author":"F Al Sabie","year":"2021","unstructured":"Al Sabie F, Tariq Z, Erickson D, Donegan D (2021) Association between prolactinoma and body mass index. Endocr Pract 27(4):312\u2013317. https:\/\/doi.org\/10.1016\/j.eprac.2020.09.001","journal-title":"Endocr Pract"},{"key":"1184_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13098-015-0094-4","volume":"7","author":"NA Pala","year":"2015","unstructured":"Pala NA, Laway BA, Misgar RA, Dar RA (2015) Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline. Diabetol Metab Syndr 7:99. DOI:https:\/\/doi.org\/10.1186\/s13098-015-0094-4","journal-title":"Diabetol Metab Syndr"},{"issue":"2","key":"1184_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4103\/2230-8210.176346","volume":"20","author":"NA Pala","year":"2016","unstructured":"Pala NA, Laway BA, Misgar RA, Shah ZA, Gojwari TA, Dar TA (2016) Profile of leptin, adiponectin, and body fat in patients with hyperprolactinemia: response to treatment with cabergolineemclose. Indian J Endocrinol Metab 20(2):177\u201381. https:\/\/doi.org\/10.4103\/2230-8210.176346","journal-title":"Indian J Endocrinol Metab"},{"key":"1184_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-12114-7_1","volume":"846","author":"N Ben-Jonathan","year":"2015","unstructured":"Ben-Jonathan N, Hugo E (2015) Prolactin (PRL) in adipose tissue: regulation and functions. Adv Exp Med Biol 846:1\u201335. DOI:https:\/\/doi.org\/10.1007\/978-3-319-12114-7_1","journal-title":"Adv Exp Med Biol"},{"issue":"9","key":"1184_CR40","doi-asserted-by":"publisher","first-page":"e12702","DOI":"10.1111\/jne.12702","volume":"31","author":"RA Augustine","year":"2019","unstructured":"Augustine RA, Knowles PJ, Khant Aung Z, Grattan DR, Ladyman SR (2019) Impaired hypothalamic leptin sensitivity in pseudopregnant rats treated with chronic prolactin to mimic pregnancy. J Neuroendocrinol 31(9):e12702. DOI:https:\/\/doi.org\/10.1111\/jne.12702","journal-title":"J Neuroendocrinol"},{"issue":"10","key":"1184_CR41","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1523\/jneurosci.4415-12.2013","volume":"33","author":"N Roman\u00f2","year":"2013","unstructured":"Roman\u00f2 N, Yip SH, Hodson DJ, Guillou A, Parnaudeau S, Kirk S, Tronche F, Bonnefont X, Le Tissier P, Bunn SJ, Grattan DR, Mollard P, Martin AO (2013) Plasticity of hypothalamic dopamine neurons during lactation results in dissociation of electrical activity and release. J Neurosci 33(10):4424\u20134433. DOI:https:\/\/doi.org\/10.1523\/jneurosci.4415-12.2013","journal-title":"J Neurosci"},{"issue":"2","key":"1184_CR42","doi-asserted-by":"publisher","first-page":"T101","DOI":"10.1530\/joe-15-0213","volume":"226","author":"DR Grattan","year":"2015","unstructured":"Grattan DR (2015) 60 years of neuroendocrinology: the hypothalamo-prolactin axis. J Endocrinol 226(2):T101\u2013T122. https:\/\/doi.org\/10.1530\/joe-15-0213","journal-title":"J Endocrinol"},{"issue":"5","key":"1184_CR43","doi-asserted-by":"publisher","first-page":"473","DOI":"10.4158\/ep-2018-0034","volume":"24","author":"CT Lim","year":"2018","unstructured":"Lim CT, Korbonits M (2018) Update on the clinicopathology of pituitary adenomas. Endocr Pract 24(5):473\u2013488. https:\/\/doi.org\/10.4158\/ep-2018-0034","journal-title":"Endocr Pract"},{"issue":"4","key":"1184_CR44","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1530\/eje-12-0763","volume":"168","author":"T Cuny","year":"2013","unstructured":"Cuny T, Pertuit M, Sahnoun-Fathallah M, Daly A, Occhi G, Odou MF, Tabarin A, Nunes ML, Delemer B, Rohmer V, Desailloud R, Kerlan V, Chabre O, Sadoul JL, Cogne M, Caron P, Cortet-Rudelli C, Lienhardt A, Raingeard I, Guedj AM, Brue T, Beckers A, Weryha G, Enjalbert A, Barlier A (2013) Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don\u2019t forget MEN1 genetic analysis. Eur J Endocrinol 168(4):533\u2013541. DOI:https:\/\/doi.org\/10.1530\/eje-12-0763","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1184_CR45","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1089\/gtmb.2018.0133","volume":"22","author":"FN Tuncer","year":"2018","unstructured":"Tuncer FN, \u00c7ift\u00e7i Do\u011fan\u015fen S, Serbest E, Tanr\u0131kulu S, Ekici Y, Bilgi\u00e7 B, Yarman S (2018) Screening of AIP gene variations in a cohort of Turkish patients with young-onset sporadic hormone-secreting pituitary adenomas. Genet Test Mol Biomarkers 22(12):702\u2013708. https:\/\/doi.org\/10.1089\/gtmb.2018.0133","journal-title":"Genet Test Mol Biomarkers"},{"issue":"5","key":"1184_CR46","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1399-0004.2010.01406.x","volume":"78","author":"CA Stratakis","year":"2010","unstructured":"Stratakis CA, Tichomirowa MA, Boikos S, Azevedo MF, Lodish M, Martari M, Verma S, Daly AF, Raygada M, Keil MF, Papademetriou J, Drori-Herishanu L, Horvath A, Tsang KM, Nesterova M, Franklin S, Vanbellinghen JF, Bours V, Salvatori R, Beckers A (2010) The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin Genet 78(5):457\u2013463. DOI:https:\/\/doi.org\/10.1111\/j.1399-0004.2010.01406.x","journal-title":"Clin Genet"},{"key":"1184_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9062003","author":"I Bilbao Garay","year":"2020","unstructured":"Bilbao Garay I, Daly AF, Ega\u00f1a N, Zunzunegi Beckers A (2020) Pituitary disease in AIP mutation-positive familial isolated pituitary adenoma (FIPA): a kindred-based overview. J Clin Med. https:\/\/doi.org\/10.3390\/jcm9062003","journal-title":"J Clin Med"},{"issue":"4","key":"1184_CR48","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.nec.2019.05.001","volume":"30","author":"CM Faltermeier","year":"2019","unstructured":"Faltermeier CM, Magill ST, Blevins LS Jr, Aghi MK (2019) Molecular biology of pituitary adenomas. Neurosurg Clin N Am 30(4):391\u2013400. https:\/\/doi.org\/10.1016\/j.nec.2019.05.001","journal-title":"Neurosurg Clin N Am"},{"issue":"3","key":"1184_CR49","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000486280","volume":"89","author":"T Breil","year":"2018","unstructured":"Breil T, Lorz C, Choukair D, Mittnacht J, Inta I, Klose D, Jesser J, Schulze E, Bettendorf M (2018) Clinical features and response to treatment of prolactinomas in children and adolescents: a retrospective single-centre analysis and review of the literature. Horm Res Paediatr 89(3):157\u2013165. https:\/\/doi.org\/10.1159\/000486280","journal-title":"Horm Res Paediatr"},{"issue":"7","key":"1184_CR50","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","volume":"84","author":"J Verhelst","year":"1999","unstructured":"Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84(7):2518\u20132522. DOI:https:\/\/doi.org\/10.1210\/jcem.84.7.5810","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1184_CR51","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","volume":"86","author":"A Di Sarno","year":"2001","unstructured":"Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86(11):5256\u20135261. DOI:https:\/\/doi.org\/10.1210\/jcem.86.11.8054","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1184_CR52","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1530\/eje-09-0012","volume":"160","author":"E Delgrange","year":"2009","unstructured":"Delgrange E, Daems T, Verhelst J, Abs R, Maiter D (2009) Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 160(5):747\u2013752. DOI:https:\/\/doi.org\/10.1530\/eje-09-0012","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1184_CR53","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/bf03346388","volume":"31","author":"L Vilar","year":"2008","unstructured":"Vilar L, Freitas MC, Naves LA, Casulari LA, Azevedo M, Montenegro R Jr, Barros AI, Faria M, Nascimento GC, Lima JG, N\u00f3brega LH, Cruz TP, Mota A, Ramos A, Violante A, Lamounier Filho A, Gadelha MR, Czepielewski MA, Glezer A, Bronstein MD (2008) Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J Endocrinol Invest 31(5):436\u2013444. DOI:https:\/\/doi.org\/10.1007\/bf03346388","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"1184_CR54","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/er.2005-9998","volume":"27","author":"MP Gillam","year":"2006","unstructured":"Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485\u2013534. DOI:https:\/\/doi.org\/10.1210\/er.2005-9998","journal-title":"Endocr Rev"},{"issue":"6","key":"1184_CR55","doi-asserted-by":"publisher","first-page":"e14380","DOI":"10.1097\/md.0000000000014380","volume":"98","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Jin D, Lian W, Xing B, Feng M, Liu X, Wang R (2019) Clinical characteristics and surgical outcome of prolactinoma in patients under 14 years old. Medicine 98(6):e14380. DOI:https:\/\/doi.org\/10.1097\/md.0000000000014380","journal-title":"Medicine"},{"issue":"2","key":"1184_CR56","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1227\/00006123-199402000-00001","volume":"34","author":"EH Dyer","year":"1994","unstructured":"Dyer EH, Civit T, Visot A, Delalande O, Derome P (1994) Transsphenoidal surgery for pituitary adenomas in children. Neurosurgery 34(2):207\u201312. https:\/\/doi.org\/10.1227\/00006123-199402000-00001 (discussion 212)","journal-title":"Neurosurgery"},{"issue":"6","key":"1184_CR57","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/s0090-3019(02)00714-0","volume":"57","author":"T Abe","year":"2002","unstructured":"Abe T, L\u00fcdecke DK (2002) Transnasal surgery for prolactin-secreting pituitary adenomas in childhood and adolescence. Surg Neurol 57(6):369\u201378. https:\/\/doi.org\/10.1016\/s0090-3019(02)00714-0 (discussion 378\u2013379)","journal-title":"Surg Neurol"},{"issue":"2","key":"1184_CR58","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3171\/jns.1994.80.2.0209","volume":"80","author":"MD Partington","year":"1994","unstructured":"Partington MD, Davis DH, Laws ER Jr, Scheithauer BW (1994) Pituitary adenomas in childhood and adolescence. Results of transsphenoidal surgery. J Neurosurg 80(2):209\u2013216. DOI:https:\/\/doi.org\/10.3171\/jns.1994.80.2.0209","journal-title":"J Neurosurg"},{"issue":"3","key":"1184_CR59","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1515\/jpem.2000.13.3.261","volume":"13","author":"HL Fideleff","year":"2000","unstructured":"Fideleff HL, Boquete HR, Sequera A, Su\u00e1rez M, Sobrado P, Giaccio A (2000) Peripubertal prolactinomas: clinical presentation and long-term outcome with different therapeutic approaches. J Pediatr Endocrinol Metab 13(3):261\u2013267. DOI:https:\/\/doi.org\/10.1515\/jpem.2000.13.3.261","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"12","key":"1184_CR60","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1210\/jc.2007-2758","volume":"93","author":"M Ono","year":"2008","unstructured":"Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K (2008) Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 93(12):4721\u20134727. DOI:https:\/\/doi.org\/10.1210\/jc.2007-2758","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1184_CR61","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1365-2362.2010.02399.x","volume":"41","author":"WA Mann","year":"2011","unstructured":"Mann WA (2011) Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach. Eur J Clin Invest 41(3):334\u2013342. DOI:https:\/\/doi.org\/10.1111\/j.1365-2362.2010.02399.x","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"1184_CR62","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/cen.12149","volume":"79","author":"A Rastogi","year":"2013","unstructured":"Rastogi A, Bhansali A, Dutta P, Singh P, Vijaivergiya R, Gupta V, Sachdeva N, Bhadada SK, Walia R (2013) A comparison between intensive and conventional cabergoline treatment of newly diagnosed patients with macroprolactinoma. Clin Endocrinol (Oxf) 79(3):409\u2013415. https:\/\/doi.org\/10.1111\/cen.12149","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"1184_CR63","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1210\/clinem\/dgz144","volume":"105","author":"AH Zamanipoor Najafabadi","year":"2020","unstructured":"Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, Broersen LHA, van den Akker-van Marle ME, Pereira AM, Peul WC, Dekkers OM, van Furth WR, Biermasz NR (2020) Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis. J Clin Endocrinol Metab 105(3):e32\u2013e41. https:\/\/doi.org\/10.1210\/clinem\/dgz144","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1184_CR64","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s12020-018-1638-9","volume":"61","author":"E Sosa-Eroza","year":"2018","unstructured":"Sosa-Eroza E, Espinosa E, Ram\u00edrez-Renter\u00eda C, Mendoza V, Arreola R, Mercado M (2018) Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR. Endocrine 61(2):343\u2013348. DOI:https:\/\/doi.org\/10.1007\/s12020-018-1638-9","journal-title":"Endocrine"},{"issue":"4","key":"1184_CR65","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11102-008-0162-y","volume":"14","author":"A Fusco","year":"2011","unstructured":"Fusco A, Lugli F, Sacco E, Tilaro L, Bianchi A, Angelini F, Tofani A, Barini A, Lauriola L, Maira G, Pontecorvi A, de Marinis L (2011) Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma. Pituitary 14(4):351\u2013357. DOI:https:\/\/doi.org\/10.1007\/s11102-008-0162-y","journal-title":"Pituitary"},{"issue":"2","key":"1184_CR66","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11102-013-0473-5","volume":"17","author":"AG Alkabbani","year":"2014","unstructured":"Alkabbani AG, Mon SY, Hatipoglu B, Kennedy L, Faiman C, Weil RJ, Hamrahian AH (2014) Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth? Pituitary 17(2):97\u2013102. DOI:https:\/\/doi.org\/10.1007\/s11102-013-0473-5","journal-title":"Pituitary"},{"issue":"7","key":"1184_CR67","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/0002-9378(81)90553-6","volume":"139","author":"CM March","year":"1981","unstructured":"March CM, Kletzky OA, Davajan V, Teal J, Weiss M, Apuzzo ML, Marrs RP, Mishell DR Jr (1981) Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 139(7):835\u2013844. DOI:https:\/\/doi.org\/10.1016\/0002-9378(81)90553-6","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"1184_CR68","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1210\/jcem-68-2-412","volume":"68","author":"J Schlechte","year":"1989","unstructured":"Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68(2):412\u2013418. DOI:https:\/\/doi.org\/10.1210\/jcem-68-2-412","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01184-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-021-01184-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01184-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T10:50:15Z","timestamp":1644231015000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-021-01184-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,13]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1184"],"URL":"https:\/\/doi.org\/10.1007\/s11102-021-01184-x","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,13]]},"assertion":[{"value":"30 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no potential conflict of interest in relation to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by local ethics committee (Approval Number: 2019\/14\u201324, Project Number: GO 19\/476).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The requirement for informed consent was waived owing to the retrospective nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}